Records containing: Rheumatoid Arthritis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2023-12-05Central Aspects of Pain in Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2023-12-04Analysis of B Cells From Autoimmune Individuals
-
CLINICAL_TRIALS study record update · 2023-11-30Phase 1 Study of Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2023-11-30Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
-
CLINICAL_TRIALS study record update · 2023-11-28A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab (TCZ) in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current DMARD Therapy
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2023-11-27educAR: Validation of a Double Educational Strategy to Improve Therapeutic Adherence in Rheumatoid Arthritis.
-
CLINICAL_TRIALS study record update · 2023-11-27Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Low Bone Mass
-
CLINICAL_TRIALS study record update · 2023-11-22A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Moderate to Severe Active Rheumatoid Arthritis Subjects With Inadequate Response to csDMARDs.
-
CLINICAL_TRIALS study record update · 2023-11-22A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
-
CLINICAL_TRIALS study record update · 2023-11-21The Effect of Ultrasonographic Cartilage Thickness and Quadriceps/Hamstring Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2023-11-21Temporomandibular Joint in Patients With Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2023-11-18A Phase 3, Randomized, Double-Blind, Positive-controlled, Head-to-Head Monotherapy Study Comparing TLL-018 to Tofacitinib in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
-
CLINICAL_TRIALS study record update · 2023-11-18BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)
-
CLINICAL_TRIALS study record update · 2023-11-18Diagnostic Value of SonoElastography in Evaluation of Median Nerve Changes With Rheumatoid Arthritis Patients Without Symptoms of Carpal Tunnel Syndrome
-
CLINICAL_TRIALS study record update · 2023-11-18Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial
-
CLINICAL_TRIALS study record update · 2023-11-18Efficacy and Safety of Baricitinib in Different Doses for the Treatment of Moderate to Severe Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2023-11-18A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®
-
CLINICAL_TRIALS study record update · 2023-11-18Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment: a Blinded Randomized Superiority Trial
-
CLINICAL_TRIALS study record update · 2023-11-13A Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study of DRL_AB, US Licensed Reference Abatacept (Orencia®) and EU Approved Reference (Orencia®), Administered by the Subcutaneous Route to Male Normal Healthy Volunteers
-
CLINICAL_TRIALS study record update · 2023-11-13A Multi-Center, Open-Label Study to Evaluate the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Using an Electrochemiluminescent Immuno-Assay
-
CLINICAL_TRIALS study record update · 2023-11-09A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement
-
CLINICAL_TRIALS study record update · 2023-11-07A Double-blind, Multi-center, Randomized, Placebo-controlled Study of the Safety and Efficacy of 12 Weeks Extended Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients naïve to DMARD Treatment
-
CLINICAL_TRIALS study record update · 2023-11-07Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Rheumatoid Arthritis Patients
-
CLINICAL_TRIALS study record update · 2023-11-03A Randomized, Double-blind, Dose-escalating, Placebo-controlled Phase Ib Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.
-
CLINICAL_TRIALS study record update · 2023-11-02Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis